Summit Therapeutics (SMMT) Change in Accured Expenses (2019 - 2026)

Summit Therapeutics has reported Change in Accured Expenses for 8 years, with the latest figure at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 170.45% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at $163000.0 (down 98.43% YoY), and the FY2025 full-year result was $2.9 million, down 55.64% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.1 million, up from -$4.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $6.3 million in Q4 2024, with the low at -$5.6 million in Q3 2023.
• Historically, Change in Accured Expenses has averaged $631529.4 across 5 years, with a median of $945000.0 in 2025.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 2598.58% — and 2023, when it soared 15388.57%.
• Summit Therapeutics' Change in Accured Expenses stood at -$35000.0 in 2022, then soared by 15388.57% to $5.4 million in 2023, then increased by 17.04% to $6.3 million in 2024, then plunged by 171.66% to -$4.5 million in 2025, then soared by 74.71% to -$1.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.1 million (Q1 2026), -$4.5 million (Q4 2025), and $945000.0 (Q3 2025), per Business Quant data.